MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Moderna, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026
$226.89+8.88 (+4.07%)
Close on Oct 19, 2026
- Market cap
- $90.30B
- P/E (TTM)
- –
- Dividend yield
- –
Moderna, Inc. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net product sales | $94.00M | $352.00M | $646.00M | $973.00M | $114.00M | $86.00M | $938.00M | $1.82B | $184.00M | $167.00M | $2.79B | $1.76B | 64.8% | -17.5% |
| COVID | $91.00M | $345.00M | $642.00M | $971.00M | $114.00M | $84.00M | $923.00M | $1.81B | $184.00M | $167.00M | $2.79B | $1.76B | 62.8% | -20.2% |
| Other revenue | $51.00M | $37.00M | $32.00M | $43.00M | $28.00M | $22.00M | $28.00M | $42.00M | $57.00M | $0 | $18.00M | $74.00M | 35.2% | +82.1% |
| Stand-ready manufacturing revenue | $31.00M | $32.00M | – | – | $17.00M | $12.00M | – | – | – | – | – | – | 21.4% | +82.4% |
| Collaboration revenue (Note 5) | $15.00M | $5.00M | $1.00M | $7.00M | $4.00M | $1.00M | $13.00M | $28.00M | $7.00M | $0 | $20.00M | $30.00M | 10.3% | +275.0% |
| Licensing and royalty revenue | $3.00M | $0 | – | $2.00M | $2.00M | $8.00M | $5.00M | $7.00M | $30.00M | $0 | $0 | $0 | 2.1% | +50.0% |
| RSV | $3.00M | $7.00M | $4.00M | $2.00M | $0 | $2.00M | $15.00M | $10.00M | $0 | $0 | $0 | $0 | 2.1% | – |
| Grant revenue | $2.00M | $0 | $2.00M | $14.00M | $5.00M | $1.00M | $10.00M | $7.00M | $20.00M | $0 | – | $44.00M | 1.4% | -60.0% |
| Other revenue | – | – | – | $20.00M | $17.00M | $12.00M | – | $0 | $0 | $0 | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Moderna's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.